BioSpace News Archive

Selexis SA, a JSR Life Sciences company, and SpyBiotech, a biotechnology company with a novel vaccine platform, have signed a commercial license agreement (CLA) to advance SPYVLP102, SpyBiotech’s lead vaccine program for human cytomegalovirus (HCMV)

Waters Corporation (NYSE:WAT) today introduced a new peptide multi-attribute method (MAM) workflow for the Waters™ BioAccord™ LC-MS System, enabling drug development, manufacturing, and QC scientists to monitor efficacy and safety through the analysis of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs.

Boston Pharmaceuticals announced today a pioneering three-year out-license and option agreement with GlaxoSmithKline PLC (LSE/NYSE: GSK). Boston Pharmaceuticals will become a preferred GSK partner for select pre-phase 2 programs. This new agreement builds on the relationship established in 2018 with Boston Pharmaceutic

Legend received approximately $659.8 million in gross proceeds through share capital increases during 2020, including a successful Nasdaq IPO with aggregate gross proceeds of $487.3 million.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.

Acuity Spatial Genomics Announces Formation to Open up New Frontiers for in situ , Spatial 3D Genomics Acuity Technology Enables the Possibility to See the 3D Genome in situ and at Single-Cell and Sub-Cellular Resolution

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced new data from a preclinical study of its drug candidate CF602 in the treatment of erectile dysfunction in diabetes experimental model.

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced the publication of a peer-reviewed case report analyzing the clinical outcomes of Zofin treatment in three critically ill patients suffering from severe, multi-organ complications induced by COVID-19 infection.

Ms. Haukioja will leverage more than 25 years of progressive pharmaceutical experience to provide strategic guidance to ZYUS’ clinical trial programs

RTW Investments, LP will provide UroGen with an upfront cash payment of $75 million and will receive tiered future payments based on worldwide annual net product sales of Jelmyto ® and UGN-102, if approved